Brain Wealthy
    What's Hot

    Bridging the Gender Gap: Inspiring Words from the Women Making Waves on Starship | Annie Handrick | | Starship Technologies | March 2023

    March 8, 2023

    AI apps like ChatGPT may finally kill the cover letter

    March 8, 2023

    Snow Crash author Neal Stephenson on the metaverse, making movies, climate fears

    March 6, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

      February 2, 2023

      How anxiety came to dominate the big business of medical marijuana cards in Pa.

      February 2, 2023

      How to Reduce Anxiety in Stressful Situations

      February 2, 2023

      The cat in boots The last wish taught me about anxiety

      February 2, 2023

      Inseparable cat trio with ‘separation anxiety brothers’ find new home

      February 2, 2023
    • Emotion

      Leigh-Anne Pinnock shares emotional post about embarking on her solo career

      February 2, 2023

      Ontario paramedic emotional during last radio call

      February 2, 2023

      A Pianist Faces Death and Recorded Music of Unspeakable Emotions

      February 2, 2023

      Return of home post linking Gichaara to ancestors is emotional for north coast nation

      February 2, 2023

      Mother of two sues New York school district for ‘mental distress’ caused by mask enforcement

      February 2, 2023
    • Neurology

      Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

      February 2, 2023

      REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

      February 2, 2023

      Aducanumab for the treatment of Alzheimer’s disease

      February 2, 2023

      Potential for Effective Comparative Studies and Treatment Approval in Epilepsy Care: Anup Patel, MD

      February 2, 2023

      Head injury does not predict memory impairment in NFL retirees, UT Southwestern study shows: Newsroom

      February 2, 2023
    • Sleep

      Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

      February 2, 2023

      Get a better night’s sleep with better pillows from The Pillow Bar in Dallas

      February 2, 2023

      Is it okay to sleep with a necklace on?

      February 2, 2023

      Does tart cherry juice improve sleep?

      February 2, 2023

      Social Jet Lag, Sleep Chronotypes, and Why We Gotta Close Our Eyes and Embrace It

      February 2, 2023
    • Brain Research

      spark!Talk – video available online

      February 2, 2023

      Studies have found that obesity-related neurodegeneration mimics Alzheimer’s disease.newsroom

      February 2, 2023

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023
    Brain Wealthy
    Home»Neurology»Helius Medical Technologies, Inc. announces the participation of the New England Center in New England.news
    Neurology

    Helius Medical Technologies, Inc. announces the participation of the New England Center in New England.news

    brainwealthy_vws1exBy brainwealthy_vws1exJanuary 10, 2023No Comments6 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    — A fifth Center of Excellence has been added to the company-sponsored, multicenter, open-label, observational intervention trial to assess the impact of subject adherence.PoNS®Treatment for improvement of walking in multiple sclerosis —

    NEWTOWN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”) is a neurotech company focused on neurological health. company and today announced its addition. to his Therapeutic Experience Program (TEP) at the Center for Neurology in New England, PC (“NCNE”). In this company-sponsored, observational, open-label study designed to evaluate the impact of subject adherence to portable neuromodulatory stimulator (PoNS) therapy in patients with multiple sclerosis (MS), NCNE has partnered with other will join his four Centers of Excellence in The initiative will be led by NCNE’s Director of Medical, Dr. Salvatore Napoli.

    “Dr. Napoli and his team are important contributors to our PTAP program and we are pleased that they are participating in the TEP study. An acclaimed medical center known for its high-touch, integrated approach to treating disease, said Helius Chief Antonella Favit-Van Pelt, MD, Ph.D. official.

    “It is well established that disease progression can be managed by advanced pharmacological and non-pharmacologic therapeutic interventions in many people suffering from the physical symptoms of multiple sclerosis. It has demonstrated the ability to improve gait and balance in patients and we are excited to include this important treatment in our broad range of high quality neurological care,” said Dr. Napoli. .

    About the New England Neurology Center

    The Neurology Center of New England is a comprehensive neurocare center dedicated to the diagnosis, care and management of patients with neurological diseases and syndromes. NCNE manages patients with MS, migraine and other headache syndromes, Parkinson’s disease, neurological disorders, seizure disorders and epilepsy, dementia and memory impairment, numbness, spasticity/dystonia, and more.

    About the treatment experience program

    The Therapeutic Experience Program is a Helius-sponsored, open-label, observational, interventional, multicenter outcomes research trial designed to assess adherence to on-label PoNS therapy to improve gait disturbance in MS patients in a real-world setting. I’m here. This study will assess subject adherence to PoNS therapy, which combines a PoNS device and physical therapy, to better understand the relationship between treatment regimen adherence and therapeutic functional outcomes. The primary endpoint of this study was gait improvement from the end of supervised treatment (Phase 1) to the end of unsupervised treatment (Phase 2) in relation to the subject’s adherence to her PoNS therapy. is maintained. Secondary endpoints were improvement in gait and balance impairment over time, and clinical global impression of change.

    The study will be conducted at 10-12 Centers of Excellence in the United States, with an estimated 4 PoNS devices per site. Registration will begin in the fourth quarter of 2022 and will continue until 2023. A total of 50 to 60 of her MS patients are expected to participate in this program.

    About Helius Medical Technologies

    Helius Medical Technologies is a leading neurotech company in the medical device space focused on neurological disorders, using non-implantable platform technology that amplifies the brain’s compensatory capacity and promotes neuroplasticity. We aim to improve the lives of those we deal with. Our first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, please visit www.heliusmedical.com.

    About PoNS devices and PoNS therapy

    The Portable Neuromodulation Stimulator is an innovative non-surgical medical device that includes a controller and mouthpiece that provides electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as short-term treatment of gait disturbance due to mild to moderate symptoms due to MS, and will be used as an adjunct to a supervised therapeutic exercise program in a 22-year-old patient. The above is prescription only.

    PoNS is also licensed for sale in Canada for two indications: Used in conjunction with physical therapy. (ii) used as a short-term treatment (14 weeks) for gait disturbances due to mild and moderate symptoms of MS, combined with physical therapy; PoNS is also licensed for sale in Australia for short-term use by health care professionals as an adjunct to therapeutic exercise programs to improve balance and gait. For more information, please visit www.ponstherapy.com.

    Attention Disclaimer

    Certain statements in this news release are not historical facts and constitute forward-looking statements or forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and the Canadian Securities Act. . All statements other than statements of historical fact contained in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by words such as “believe,” “expect,” “continue,” “will,” “goal,” “objective,” or similar expressions. Such forward-looking statements include, among other things, the expected enrollment, patient participation, and other details related to the results of the TEP study, and that a key opinion leader in the management of MS is committed to his PoNS® therapy. Includes statements about the ability to build knowledge and advise. the wider medical community.

    There can be no assurance that such statements will prove to be accurate, and actual results and future events may differ materially from those expressed or implied by such statements. Significant factors that could cause our results to differ materially from our expectations include our capital requirements to meet our business goals, the impact of the COVID-19 pandemic, and our ability to train our physical therapists in supervising use. includes the uncertainty associated with our ability to secure contracts with rehabilitation clinics for PoNS treatment; our ability to obtain nationwide Medicare coverage and obtain reimbursement codes so that PoNS devices are covered by Medicare and Medicaid; Our ability to build commercial infrastructure, secure state sales licenses, build commercial teams, build relationships with key opinion leaders, neurological experts and neurorehabilitation centers, and increase market awareness of PoNS devices, Future Clinical Trial and Clinical Development Processes, Manufacturing and Supply Chain Risks, Product Development Processes and FDA Regulatory Submissions section, from time to time, Zion’s review and approval process, other developmental activities, ongoing governmental regulations, and other risks, and its other filings with the U.S. Securities and Exchange Commission and Canadian securities regulators. documents are available at www.sec.gov or www.sedar.com.

    Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release and the Company undertakes no obligation to update any forward-looking statements or that actual results may differ from such statements. We do not undertake any obligation to update any possible reasons. required by law.

    Investor Information Inquiries

    Lisa M. Wilson, In-Site Communications, Inc.

    Phone: 212-452-2793

    E: lwilson@insitecony.com



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleBrain Tumor Nonprofit StacheStrong Donates $110,000 to Launch SNS Neurosurgeon Training Program
    Next Article Consultant veterinary neurosurgeon joins Swindon Animal Hospital
    brainwealthy_vws1ex
    • Website

    Related Posts

    Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

    February 2, 2023

    REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

    February 2, 2023

    Aducanumab for the treatment of Alzheimer’s disease

    February 2, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.